Unknown

Dataset Information

0

Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection.


ABSTRACT: Respiratory and gastrointestinal symptoms are the predominant clinical manifestations of the coronavirus disease 2019 (COVID-19). Infecting intestinal epithelial cells, the severe acute respiratory syndrome coronavirus-2 may impact on host's microbiota and gut inflammation. It is well established that an imbalanced intestinal microbiome can affect pulmonary function, modulating the host immune response ("gut-lung axis"). While effective vaccines and targeted drugs are being tested, alternative pathophysiology-based options to prevent and treat COVID-19 infection must be considered on top of the limited evidence-based therapy currently available. Addressing intestinal dysbiosis with a probiotic supplement may, therefore, be a sensible option to be evaluated, in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration in preventing and treating COVID-19 pneumonia.

SUBMITTER: Spagnolello O 

PROVIDER: S-EPMC8089442 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8826744 | biostudies-literature
| S-EPMC7597425 | biostudies-literature
| S-EPMC7883063 | biostudies-literature
| S-EPMC9575645 | biostudies-literature
| S-SCDT-10_1038-S44318-024-00061-0 | biostudies-other
| S-EPMC7368885 | biostudies-literature
| S-EPMC8014204 | biostudies-literature
| 12454 | ecrin-mdr-crc
2013-07-31 | E-GEOD-47960 | biostudies-arrayexpress
2013-07-31 | E-GEOD-47961 | biostudies-arrayexpress